Compare DexCom, Inc. (DXCM) vs Kenvue Inc. Common Stock (KVUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kenvue Inc. Common Stock — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Kenvue Inc. Common Stock trades at $17.68 (market cap $34.06B). The key difference: DexCom, Inc. and Kenvue Inc. Common Stock are close in size by market cap, and Kenvue Inc. Common Stock pays a 4.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KVUE | |
|---|---|---|
Market Cap | $31.86B | $34.06B |
Volume | 3,607,070 | 23,267,228 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $19.83 |
52-Week Low | $54.84 | $14.11 |
Typical Hold Time | 62 Days | — |
Enterprise Value | $31.32B | $41.56B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kenvue Inc. Common Stock
Kenvue is a consumer health company that markets personal care, self-care, and skin health products. Its brands include Tylenol, Listerine, Neutrogena, Johnson’s, BAND-AID Brand, Aveeno, and Zyrtec.
Read more on KVUE →
